Inadequate antimicrobial therapy is a critical determinant of survival in patients admitted to ICU, with overwhelming infection requiring renal replacement therapy (RRT). Guidelines for effective dosing are not available because RRT can be significantly different between ICUs, resulting in antimicrobial pharmacokinetics that could be inadequate in up to 40% of antimicrobial doses. Developing an evidenced based antimicrobial dosing guideline is of global significance and should be considered a priority to improving clinical outcomes for patients with significant infections requiring RRT.

The aim of the SMARRT Study is to develop optimised antimicrobial dosing guidelines for ICU patients with life-threatening infections that account for patient characteristics and the type of RRT they are prescribed. This study will focus on piperacillin/tazobactam, meropenem, vancomycin and linezolid.